**Table S1**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **MET-hours per week** | **Cases** | **Age-adjusted HR (95% CI)** | **Cases** | **Multivariate-adjusted HR1 (95% CI)** | **Cases** | **Latency multivariate-adjusted HR2 (95% CI)** |
| All-Cancer |  |  |  |  |  |  |
| 0 – 34.6 | 776 | 1.0 (Ref) | 742 | 1.0 (Ref) | 633 | 1.0 (Ref) |
| 34.7 – 76.3 | 480 | 1.03 (0.91, 1.16) | 464 | 1.02 (0.90, 1.16) | 407 | 1.04 (0.91, 1.19) |
| 76.4 – 116.7 | 456 | 1.01 (0.89, 1.14) | 441 | 0.96 ( (0.84, 1.10) | 370 | 0.93 (0.80, 1.07) |
| 116.8 – 463.4 | 474 | 1.00 (0.88, 1.13) | 460 | 0.88† (0.76, 1.00) | 409 | 0.89 (0.91, 1.19) |
| *P for trend* |  | 0.90 |  | 0.04 |  | 0.06 |
| Breast Cancer |  |  |  |  |  |  |
| 0 – 34.6 | 171 | 1.0 (Ref) | 163 | 1.0 (Ref) | 142 | 1.0 (Ref) |
| 34.7 – 76.3 | 120 | 1.04 (0.81, 1.33) | 113 | 0.97 (0.74, 1.25) | 101 | 0.97 (0.74, 1.29) |
| 76.4 – 116.7 | 98 | 0.99 (0.76, 1.29) | 94 | 0.93 (0.70, 1.23) | 82 | 0.91 (0.67, 1.22) |
| 116.8 – 463.4 | 63 | 0.93 (0.69, 1.25) | 63 | 0.92 (0.67, 1.26) | 55 | 0.90 (0.64, 1.26) |
| *P for trend* |  | 0.64 |  | 0.54 |  | 0.45 |
| Colon Cancer |  |  |  |  |  |  |
| 0 – 34.6 | 73 | 1.0 (Ref) | 69 | 1.0 (Ref) | 59 | 1.0 (Ref) |
| 34.7 – 76.3 | 40 | 0.97 (0.65, 1.46) | 40 | 1.05 (0.69, 1.60) | 34 | 1.02 (0.64, 1.61) |
| 76.4 – 116.7 | 37 | 0.93 (0.61, 1.43) | 37 | 0.97 (0.62, 1.52) | 33 | 0.97 (0.60, 1.57) |
| 116.8 – 463.4 | 31 | 0.73 (0.47, 1.15) | 31 | 0.65† (0.40, 1.06) | 27 | 0.61† (0.36, 1.04) |
| *P for trend* |  | 0.20 |  | 0.11 |  | 0.09 |
| Prostate Cancer |  |  |  |  |  |  |
| 0 – 34.6 | 90 | 1.0 (Ref) | 89 | 1.0 (Ref) | 66 | 1.0 (Ref) |
| 34.7 – 76.3 | 67 | 1.16 (0.83, 1.61) | 66 | 1.15 (0.81, 1.62) | 56 | 1.28 (0.87, 1.88) |
| 76.4 – 116.7 | 82 | 1.20 (0.87, 1.67) | 81 | 1.20 (0.85, 1.70) | 72 | 1.37 (0.94, 2.01) |
| 116.8 – 463.4 | 127 | 1.21 (0.90, 1.64) | 122 | 1.24 (0.89, 1.72) | 108 | 1.36† (0.95, 1.96) |
| *P for trend* |  | 0.23 |  | 0.21 |  | 0.12 |
| Lung Cancer |  |  |  |  |  |  |
| 0 – 34.6 | 90 | 1.0 (Ref) | 85 | 1.0 (Ref) | 71 | 1.0 (Ref) |
| 34.7 – 76.3 | 34 | 0.87 (0.57, 1.31) | 33 | 1.04 (0.68, 1.60) | 30 | 1.18 (0.75, 1.86) |
| 76.4 – 116.7 | 37 | 1.05 (0.69, 1.58) | 34 | 1.12 (0.72, 1.75) | 30 | 1.20 (0.75, 1.93) |
| 116.8 – 463.4 | 30 | 0.81 (0.52, 1.25) | 29 | 0.71 (0.44, 1.17) | 26 | 0.82 (0.49, 1.38) |
| *P for trend* |  | 0.50 |  | 0.32 |  | 0.66 |
| Endometrial Cancer |  |  |  |  |  |  |
| 0 – 34.6 | 47 | 1.0 (Ref) | 42 | 1.0 (Ref) | 37 | 1.0 (Ref) |
| 34.7 – 76.3 | 28 | 0.87 (0.53, 1.43) | 24 | 0.81 (0.46, 1.42) | 23 | 0.84 (0.47, 1.50) |
| 76.4 – 116.7 | 24 | 0.88 (0.52, 1.48) | 23 | 0.91 (0.52, 1.60) | 17 | 0.72 (0.39, 1.36) |
| 116.8 – 463.4 | 18 | 0.96 (0.54, 1.69) | 15 | 0.93 (0.49, 1.74) | 13 | 0.88 (0.44, 1.73) |
| *P for trend* |  | 0.81 |  | 0.84 |  | 0.51 |
| Non-Hodgkin Lymphoma | | |  |  |  |  |
| 0 – 34.6 | 36 | 1.0 (Ref) | 35 | 1.0 (Ref) | 32 | 1.0 (Ref) |
| 34.7 – 76.3 | 17 | 0.69 (0.38, 1.27) | 16 | 0.62 (0.33, 1.19) | 16 | 0.67 (0.35, 1.29) |
| 76.4 – 116.7 | 14 | 0.57† (0.29, 1.09) | 14 | 0.49\* (0.25, 0.98) | 9 | 0.34\*\* (0.15, 0.76) |
| 116.8 – 463.4 | 26 | 1.01 (0.59, 1.75) | 26 | 0.71 (0.38, 1.31) | 23 | 0.68 (0.35, 1.31) |
| *P for trend* |  | 0.89 |  | 0.25 |  | 0.15 |
| Leukemia |  |  |  |  |  |  |
| 0 – 34.6 | 36 | 1.0 (Ref) | 34 | 1.0 (Ref) | 28 | 1.0 (Ref) |
| 34.7 – 76.3 | 15 | 0.64 (0.34, 1.20) | 15 | 0.63 (0.33, 1.22) | 11 | 0.54 (0.25, 1.14) |
| 76.4 – 116.7 | 16 | 0.69 (0.37, 1.30) | 15 | 0.58 (0.29, 1.14) | 12 | 0.53† (0.25, 1.21) |
| 116.8 – 463.4 | 23 | 0.94 (0.53, 1.66) | 23 | 0.71 (0.37, 1.35) | 22 | 0.80 (0.40, 1.57) |
| *P for trend* |  | 0.83 |  | 0.29 |  | 0.56 |
| Hematological Cancers | |  |  |  |  |  |
| 0 – 34.6 | 73 | 1.0 (Ref) | 70 | 1.0 (Ref) | 61 | 1.0 (Ref) |
| 34.7 – 76.3 | 33 | 0.67† (0.44, 1.03) | 32 | 0.63\* (0.40, 0.99) | 28 | 0.61\* (0.37, 0.99) |
| 76.4 – 116.7 | 30 | 0.61\* (0.39, 0.96) | 29 | 0.52\*\* (0.32, 0.84) | 21 | 0.41\*\* (0.24, 0.71) |
| 116.8 – 463.4 | 50 | 0.97 (0.66, 1.44) | 50 | 0.70 (0.45, 1.09) | 46 | 0.73 (0.45, 1.16) |
| *P for trend* |  | 0.77 |  | 0.10 |  | 0.13 |

1Adjusted for: age (continuous), sex (for non sex-specific cancers), ethnicity (white/other), marital status (married or living with someone/divorced, separated, or widowed/single, never married), highest level of education (high school or less/some post-high school education/post-high school certificate or degree), total household income ($0 to $49,999/$50,000 to $99,999/{greater than or equal to} $100,000), geographical area of residence (urban/rural), smoking status (current/former/never), pack-years of cigarettes (lung cancer only), alcohol consumption (grams of ethanol per day), energy intake (kilocalories per day), fibre intake (grams per day) (colon cancer only), BMI (continuous), history of cardiovascular condition (yes/no), history of respiratory condition (yes/no), family history of cancer (yes/no), menopausal status (pre-menopause/post-menopause) (breast and endometrial cancers), history of breast cancer screening (yes/no) (breast cancer only), history of colon cancer screening (yes/no) (colon cancer only), history of prostate cancer screening (yes/no) (prostate cancer only), quartiles of recreational physical activity, quartiles of household physical activity, and groups of transportation physical activity.

2 Cancers occurring less than 2 years after baseline data collection removed

\*\*p<0.01, \*p<0.05, †p<0.1